Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M282Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-38.9
Enterprise Value $M440EPS (TTM) $-0.9Operating Margin %--Piotroski F-Score1
P/E(ttm)--Beneish M-Score-12.1Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %-20.0Quick Ratio0.3Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %-14.6Current Ratio0.3Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-183.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M478ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with MNKD

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
MNKDFirst Eagle Investment 2013-03-31 Sold Out -0.0066%$2.31 - $3.56
$ 0.59-79%Sold Out0
MNKDFirst Eagle Investment 2012-12-31 Buy 0.01%$1.85 - $2.83
$ 0.59-73%New holding800,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MNKD is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

MNKD: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Castagna MichaelChief Commercial Officer 2016-08-26Buy17,500$0.78-21.79view
Castagna MichaelChief Commercial Officer 2016-08-24Buy15,000$0.87-29.89view
Castagna MichaelChief Commercial Officer 2016-08-23Buy25,000$0.94-35.11view
PFEFFER MATTHEW JCEO, CFO, Director 2016-08-15Buy25,000$0.99-38.38view
Castagna MichaelChief Commercial Officer 2016-08-12Buy25,000$1-39view
Alinaya Rosabel RealicaSVP, Prin Acctg Officer 2016-07-06Sell6,294$1.06-42.45view
Castagna MichaelChief Commercial Officer 2016-05-17Buy50,000$0.93-34.41view
Martens JuergenCorporate VP and COO 2015-05-21Buy20,000$4.57-86.65view
Edstrom HakanPresident & CEO 2015-04-24Sell73,460$4.83-87.37view
Edstrom HakanPresident & CEO 2015-03-27Sell73,460$5.21-88.29view

Press Releases about MNKD :

Quarterly/Annual Reports about MNKD:

News about MNKD:

Articles On GuruFocus.com
Why MannKind Could Be a Value Trap Jan 04 2016 
MannKind Corporation Disappoints with Afrezza Sales; Analysts Lower Expectations May 11 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
Analysts Weigh in on MannKind Following Q4 Results Feb 27 2015 
What to Watch for: November 3-7 Nov 04 2014 
Roche to Acquire InterMune and Deliver Hope to Patients Worldwide Aug 25 2014 
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
There is a Tide in the Affairs of MannKind: When Taken At the Flood, Will Lead to Fortune Aug 14 2014 

More From Other Websites
MannKind Corporation (MNKD) Stock: One Thing The Company Could Do To Return Value Oct 14 2016
Short Sellers Have Mixed Views on Major Biotechs Oct 12 2016
The 6 Most Shorted Nasdaq Stocks Oct 12 2016
Short Sellers Increase Bets in Major Biotechs Sep 27 2016
The 6 Most Shorted Nasdaq Stocks Sep 27 2016
Can MannKind Compete Against Mylan's EpiPen? (MNKD) Sep 26 2016
MANNKIND CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... Sep 22 2016
MNKD: How MannKind's Stock Price Fell 28% in 6 Months Sep 16 2016
MannKind Corp. :MNKD-US: Earnings Analysis: Q2, 2016 By the Numbers : September 14, 2016 Sep 14 2016
MannKind Stock: 3 Things to Watch (MNKD) Sep 13 2016
Short Sellers Run for Cover From Major Biotechs Sep 13 2016
The 6 Most Shorted Nasdaq Stocks: Short Sellers Get Choosy Sep 13 2016
MannKind developing inhalable epinephrine to challenge Mylan's EpiPen Sep 06 2016
MannKind Corporation to Present at the Rodman & Renshaw 18th Annual Global Investment Conference Sep 02 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)